Project Grant R21CA277412
Award Date 5/1/24
Completion Date 4/30/26
Dollars Obligated $412K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Beken Bio, Inc. aims to develop a highly sensitive, minimally invasive laboratory test to detect early-stage ovarian cancer by assaying relevant biomarkers on circulating extracellular vesicles in patient plasma. The project will utilize a novel technology to identify key proteins in extracellular vesicles from various ovarian cancer subtypes and employ a machine...
- This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived...
- The National Cancer Institute (NCI) awarded a $151,000 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC) to investigate the role of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The project aims to: 1) Define essential genes for the polyploid cancer cell lifecycle and its critical transition stages using CRISPR-Cas9 screening, and 2) Determine the expression of putative polyploid cancer...
- GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...
- Federal Grant Award Summary The National Cancer Institute awarded $386,700 to the Regents of the University of Minnesota under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 7, 2025, for preclinical development and validation of targeted mass spectrometry assays for serous ovarian cancer diagnosis. The project, which runs through June 30, 2027, will deliver novel parallel reaction monitoring (PRM) assays capable of differentiating serous ovarian cancer patients from...
- The National Cancer Institute awarded Massachusetts General Hospital (MGH) a Project Grant totaling $744,575 under the Cancer Cause and Prevention Research program (CFDA 93.393) on May 16, 2025, with performance through April 30, 2030. The grant supports research to define the genomic and biologic impact of LINE-1 (Long Interspersed Element-1) activity in fallopian tube epithelial cells and its contribution to high-grade serous ovarian cancer (HGSOC) pathogenesis. The research will investigate...
- This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Alabama a $631,621 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an integrated top-down proteomics and phosphoproteomics platform for analyzing patient-derived ovarian cancer spheroids. The award, effective August 13, 2025, through July 31, 2028, supports the creation of personalized intact proteome maps that characterize disease states and identify markers...
- Federal Cooperative Agreement Award Summary The Beckman Research Institute of the City of Hope received a $738,675 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop an innovative exosome-based liquid biopsy assay for the non-invasive early detection of colorectal adenomas and cancers. Awarded on March 16, 2026, with a completion date of February 28, 2031, this five-year project addresses a critical...
- This $215,985 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Leland Stanford Junior University is for a pilot study to sequence exosomal RNA from the blood and urine of 50 patients with renal cell carcinoma. The objective is to identify early biomarkers for therapeutic response to the immune checkpoint inhibitor combination of nivolumab and ipilimumab. The study will analyze changes in the exosomal proteins and RNA,...